Biophytis receives favorable recommendation from Data Monitoring Committee (DMC) based on safety analysis of Sarconeos (BIO101) to continue patients recruitment in the COVA study in COVID-19

  • The independent DMC (Data Monitoring Committee) of the COVA study recommends to continue patients recruitment into Part 2 of the phase 2-3 study following randomization of the first 155 patients
  • Efficacy data from the second Interim Analysis is expected to be reviewed by DMC in Q3 2021
  • Top line results of the full study on 310 patients are expected in Q4 2021, depending on COVID-19 pandemic